ArkBio, a biopharmaceutical company focusing on the discovery and development of therapeutics addressing unmet medical needs in pediatric and respiratory diseases, will continue to accelerate innovation and commercialization of respiratory and pediatric medicine with the fresh proceeds.
ArkBio (Chinese: 爱科百发) announced its completion of the Series D financing round on 14 July. This round was led by Loyal Valley Capital (Chinese: 正心谷资本), with the participation from C&D Emerging Industry International Investment (Chinese: 建发新兴投资), LongDa Food (Chinese: 龙大食品) and the existing investors Oriza Holdings (Chinese: 元禾控股), Qiming Venture Partners (Chinese: 启明创投), Shanghai FTZ Fund (Chinese: 上海自贸区基金及其临港新片区科创基金) and SME Development Fund (Chinese: 中小企业发展基金). The amount was undisclosed.
The funding will be used to develop more innovative drugs with clinical value for patients with pediatric and respiratory diseases globally.
Founded in 2014, ArkBio has a number of core technologies and global patents in the field of innovative drug development. It also has developed solid highly differentiated products through a combination of independent R&D and external introduction. In April, the company announced the successful results of the multicenter Phase III clinical trail AirFLO study with ziresovir in infants hospitalized with RSV. The results represent the first successful phase 3 study for an oral RSV antiviral drug globally.
ArkBio's competitors include ApicHope (Chinese: 一品红), DYNE Pharma (Chinese: 达因药业) and CR Sanjiu (Chinese: 华润三九).